Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Rimonabant likely to be priced in line with statins

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Rimonabant likely to be priced in line with statins. Pharmacoecon. Outcomes News 461, 11 (2004). https://doi.org/10.2165/00151234-200404610-00029

    Download citation

    Keywords

    • Public Health
    • Obesity
    • Health Outcome
    • Statin
    • Health Economic